Consensus $268.83M. Raises FY25 adjusted EBITDA view to $31M-$33M from $30M-$32M. “LifeMD (LFMD) had an exceptionally strong first quarter with top- and bottom-line growth both ahead of our expectations. Telehealth revenue achieved 70% year-over-year growth on a standalone basis, while our telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago period. We also achieved positive GAAP net income for the first time,” commented Marc Benathen, Chief Financial Officer of LifeMD. “We are raising our full-year 2025 guidance to reflect our strong performance to date for both revenue and adjusted EBITDA. We now expect total revenues in the range of $268 to $275 million, up from $265 to $275 million, and adjusted EBITDA in the range of $31 to $33 million, up from $30 to $32 million.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD options imply 12.4% move in share price post-earnings
- Is LFMD a Buy, Before Earnings?
- Unusually active option classes on open April 30th
- LifeMD’s Strategic Growth: Buy Rating Backed by Wegovy Integration and Future Offerings
- HIMS Stock Soars 27% as Novo Nordisk (NVO) Expands Wegovy Access to Telehealth
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue